AstraZeneca, Ionis drug fails big heart disease study in major setback
Phase 3negativeEplontersenNegative
AI Analysis
Summary
AstraZeneca and Ionis' eplontersen failed a pivotal Phase 3 study in transthyretin-mediated amyloidosis cardiomyopathy, representing a major setback that benefits rival programs from Alnylam and BridgeBio Pharma.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Eplontersen failed major heart disease study in transthyretin-mediated amyloidosis cardiomyopathy
Importance:8/10
Sentiment:
-0.95
clinical trial failurecardiologyamyloidosisnegative catalystcompetitive impact
Read the original article
Published by BioPharma Dive on July 9, 2026 11:54 AM